Amgen (AMGN) Competitors

Amgen has a net margin of 20.96% compared to Moderna's net margin of -143.55%. Amgen's return on equity of 137.41% beat Moderna's return on equity.

Amgen currently has a consensus target price of $356.62, indicating a potential downside of 5.17%. Moderna has a consensus target price of $40.00, indicating a potential downside of 26.02%. Given Amgen's stronger consensus rating and higher possible upside, research analysts plainly believe Amgen is more favorable than Moderna.

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

In the previous week, Amgen had 25 more articles in the media than Moderna. MarketBeat recorded 39 mentions for Amgen and 14 mentions for Moderna. Amgen's average media sentiment score of 1.27 beat Moderna's score of 0.60 indicating that Amgen is being referred to more favorably in the media.

Amgen has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Vertex Pharmaceuticals' return on equity.

Amgen currently has a consensus target price of $356.62, indicating a potential downside of 5.17%. Vertex Pharmaceuticals has a consensus target price of $559.61, indicating a potential upside of 17.23%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

In the previous week, Amgen had 3 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 39 mentions for Amgen and 36 mentions for Vertex Pharmaceuticals. Amgen's average media sentiment score of 1.27 beat Vertex Pharmaceuticals' score of 1.25 indicating that Amgen is being referred to more favorably in the media.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Amgen has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, AbbVie had 39 more articles in the media than Amgen. MarketBeat recorded 78 mentions for AbbVie and 39 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat AbbVie's score of 1.10 indicating that Amgen is being referred to more favorably in the media.

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.7%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Amgen pays out 70.1% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and AbbVie has raised its dividend for 53 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and lower payout ratio.

Amgen has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity.

Amgen presently has a consensus price target of $356.62, indicating a potential downside of 5.17%. AbbVie has a consensus price target of $268.10, indicating a potential upside of 3.47%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Amgen.

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.19%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.7%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Astrazeneca currently has a consensus price target of $211.00, suggesting a potential upside of 25.09%. Amgen has a consensus price target of $356.62, suggesting a potential downside of 5.17%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities analysts clearly believe Astrazeneca is more favorable than Amgen.

In the previous week, Astrazeneca had 2 more articles in the media than Amgen. MarketBeat recorded 41 mentions for Astrazeneca and 39 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Astrazeneca's score of 0.92 indicating that Amgen is being referred to more favorably in the news media.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Astrazeneca has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.